Open Access and Privacy Statement

Open Access Statement

International Journal of Drug Regulatory Affairs is committed to real and immediate Open Access for academic work. All the original articles and review papers published in this journal are open access.

Open Access:

All research articles published in IJDRA Journal are fully open access: immediately freely available to read, download and share. Articles are published under the terms of a Creative Commons license (*CC BY-NC - Creative Commons Attribution-NonCommercial License) which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

An Open Access Publication is one that meets the following two conditions:

  1. The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution & scholarly society that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.


  1. Open access is a property of individual works, not necessarily journals or publishers.
  2. Community standards, rather than copyright law, will continue to provide the mechanism for enforcement of proper attribution and responsible use of the published work, as they do now.

* Allows users to copy, distribute and transmit an article, adapt the article as long as the author is attributed and the article is not used for commercial purposes.

User Rights

All articles published as hybrid open access will be available for everyone to read, download, copy and distribute. Permitted reuse is defined by the user license CC-BY-NC.

The International Journal of Drug Regulatory Affairs also operates under the Creative Commons Licence CC-BY-NC. This allows for the reproduction of articles, free of charge, for non-commercial use only and with the appropriate citation information. All authors publishing with the IJDRA accept these as the terms of publication.

CC-BY-NC (Creative Commons Non-Commercial License): Allows others to copy and redistribute the material in any medium or format. However, the material may not be used for commercial purposes. It can be an appropriate licence for monographs because it protects print copy sales while still providing scope for users to create derivative works of the online version to the benefit of all academia.

Hybrid Open Access Publication Fee

IJDRA is an Open Access journal with subscription, although there are no Article submission charges, a fee is payable by the author or research funder to cover the costs associated with publication.

Article Processing Charges (APC):

  • No charges for Scholars living in India with BPL (Below Poverty Line)
  • No charges for Government officials from Ministry of Health (MoH)
  • No charges for Authors from Low-Income Countries*
  • No charges for an Outstanding article - decision lies on Editorial board committe
  • 2000 INR/article from Indian Authors
  • USD 30/article from Authors from Low-Middle Income Countries*
  • USD 60/article from Authors from Upper-Middle-Income Countries*
  • USD 120/article from Authors from High-Income Countries*

*Classification of world bank  (No other hidden charges) See details in Article processing Charges (APC) and waiver policy

(No other hidden charges) More detail for waiver policy.

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Complaints and Appeal Policy

The Editorial Board of the IJDRA Journal considers each complaint with due solemnity. Issues related to (a) authorship and seniority of authorship, (b) plagiarism, (c) duplicate, multiple, concurrent publication, (d) misappropriation of research results, (e) research errors and fraud, (f) violations of research standards, (g) undisclosed conflicts of interest, (h) reviewer bias or acts of harm out of competition by reviewers are serious.

Any complaint and appeal on editorial decisions, long procedural delays, and publication ethics is looked into by the Editor-in-Chief and/or the concerned Editor who had handled the manuscript. On receiving an appeal against a decision on rejection of a manuscript, the Editor-in-Chief or handling Editor considers the authors’ argument, the reviewer reports / Editorial Board comments, and decides whether (a) the appeal should be considered, or (b) the decision to reject should stand, or (c) another independent technical opinion of a subject-matter expert is required.

Authorship dispute arising during peer review or after acceptance / publication is considered to be a matter beyond the administrative scope of the Journal and are to be resolved by the authors. The journal reserves the right to terminate processing of such manuscript, or in case of a published article refer the matter to the organisation(s) to which the author(s) are affiliated for their viewpoint.

On receiving complaint about publication ethics, infringe in intellectual property rights, material inaccuracies or otherwise unlawful materials, the Editor-in-Chief in consultation with the handling Editor decides on a course of action. The investigation may require the parties involved to substantiate their claims, and the Journal will make a good faith determination whether to remove the allegedly wrongful material, and provide feedback to the complainant as per the Journal policies and guidelines. Any allegation of research misconduct or unethical behaviour shall be considered as per guidelines of the Committee on Publication Ethics (COPE). The complainant, if appropriate, is informed of the decision. Complaints about editorial content should be made to the Editor-in-Chief as soon as possible after publication.  IJDRA Editorial Board considers appeals except when they are anonymous and not substantiated.

All legal matters will remain under the jurisdiction of the court of law, New Delhi, India.

Editorial Policies and Publication Ethics

This policy serves the purpose of ensuring the best publishing practices for everyone involved in the scholarly publishing process.
The publication ethics and malpractice statements are made with reference from the Code of Conduct and Best Practice Guidelines for Journal Editors of the Committee on Publication Ethics (COPE).

Updated 10-07-2024